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A B S T R A C T
The increased expression of c-myc is related to neoplastic transformation and angiogenesis. Therefore, the assessment
of expression of c-myc in endothelial cells and neovascularization could help to determine the biological behavior of the
tumor. We analyzed neovascularization and c-myc expression in 36 medulloblastoma specimens. The results were shown
by determining immunohistochemical staining index (ISI), the sum of staining intensity (SI) and the percentage of posi-
tive cells (PPC) in the blood vessels endothelium of the tumor. We also performed the microvessel count (MVC) in 10
high-power fields (400X) with the most prominent vascularization and expressed it as microvessel density per mm2
(MVD). C-myc immunostaining intensity index in blood vessel endothelium is grouped into four groups, 0 – no reaction,
I – weak reaction (ISI = 1 or 2), II – moderate reaction (ISI = 3 or 4), III – strong reaction (ISI = 5 or 6). Statistically sig-
nificant differences (p=0.0214) have been found between groups 0 and 1 compared to groups 2 and 3. A higher percent-
age of positive cells has been found in male patients than in female ones (p=0.0483). C-myc PPC 0 or 1 has on the average
smaller density of blood vessels per mm2 than c-myc PPC 2 or 3, but the difference is not statistically significant. C-myc
ISI 0 or 1 has, on the average, smaller density of blood vessels permm2 than c-myc ISI 2 or 3, but the difference is not sta-
tistically significant.We concluded that c-myc staining intensity was associated with higher microvessels density.
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Introduction
Medulloblastoma is a malignant, invasive, neuroecto-
dermal, embrional tumor which originates from the pre-
cursors of cerebellar granular cells with predominantly
neural differentiation1–4. It represents 20% of tumors in
infants and it sporadically appears in genetic diseases
such as Turcott and Gorlin syndrome, in numerous chro-
mosomal abnormalities and more often in male children
(ratio M:F is 1.5:1)1,2. Its symptoms are related to hydro-
cephalus and leptomeningeal disease (LMD) as a conse-
quence of metastases via the cerebrospinal fluid. Extra-
cranial metastases are rare, but several cases have been
described in literature5–11.
In many experimental models, increased c-myc ex-
pression induces neoplastic cell transformation as well as
the angiogenesis12–15. The ability of c-myc to intensify
angiogenesis and lymphangiogenesis supports the theory
of its participation in the process of tumor growth and
metastasizing13–15. Uncontrolled angiogenesis has an im-
portant role in tumor growth and is an important factor
of malignancy13–15. In humans, c-myc is more frequently
expressed in solid and hematopoietic tumors, in which
tumor growth is directly correlated with the intensity of
angiogenesis. The ability of tumor cells to metastasize is
also associated with the formation of new blood vessels.
Early angiogenic changes are the consequence of myc
clonal expression in progenitor cells, while the late ones
are the consequence of local hypoxia. Increased tumor
vascularization is a poor prognostic factor15,16.
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Since brain tumors do not metastasize by lymphatics
and exceptionally rarely cause distant metastases, the es-
timate of tumor vascularization and c-myc expression
could be used to determine biological behaviour of the
tumor9–11,17. The goal of our research was to estimate the
c-myc expression in endothelial cells and to determine
the average density of blood vessels in medulloblastomas,
which could serve as predictors of aggressive behavior.
Material and Methods
Thirty-six tumor specimens were obtained from pa-
tients who underwent surgery for medulloblastoma at
the Neurosurgery Department of the »Sestre milosrd-
nice« University Hospital and the Zagreb University
Hospital Center in the period from 1997 to 2006 were an-
alyzed in our paper. Tumors were pathohistologically an-
alyzed at the »Ljudevit Jurak« Department of Pathology,
the »Sestre milosrdnice« University Hospital. The diag-
nosis of medulloblastoma was histologically confirmed in
all cases. Tumors were classified as a classic type of
medulloblastoma in 23 cases, while 13 tumors were other
medulloblastoma type according to the World Health Or-
ganization (WHO) criteria1.
Formalin fixed, paraffin embedded tissue was cut at 5
ìm thickness and stained by hematoxylin and eosin. Ad-
ditional slides were deparaffinized and stained with mo-
noclonal antibody 9E10 M3570 to c-myc (Dako Epos,
Denmark), following the Microwave Streptavidin Immu-
no-Peroxidase (MSIP) protocol on the TechMateTM Hori-
zon automated immunostainer. A breast cancer tissue ser-
ved as a positive control and the removal of the primary
antibody was used as a negative control. The immunohisto-
chemical reaction was membranous and cytoplasmatic.
The results were expressed semi-quantitatively, con-
sidering the intensity of staining and the proportion of
endothelial cells showing an unequivocal immunoreac-
tivity in 10 high-power fields (HPFs), (400x). All ana-
lyzed specimens containing only the tumor tissue and en-
dothelial cells in intratumoral vessels were counted. The
immunohistochemical staining index (ISI) was obtained
as the sum of the staining intensity (SI) and the percent-
age of positive cells (PPC): ISI=SI+PPC18,19.
SI was expressed as 0 – no reaction, 1 – weak, 2 – mod-
erate, and 3 – strong reaction, while the PPC was deter-
mined in 10 HPFs, and expressed as follows: 0 – no posi-
tive cells, 1 – 10% of positive cells, 2 – > 10 – 50 % of
positive cells, and 3 – more than 50% of positive cells.
According to the ISI, 4 groups were formed, as fol-
lows:
0 – no reaction
I – weak reaction (ISI = 1 or 2),
II – moderate reaction (ISI = 3 or 4),
III – strong reaction (ISI = 5 or 6).
The number of tumor microvessels (MVC – micro-
vessel count) was counted in the 10 most active regions
of vascularization (»hot spots«). The average MVC was
calculated from 10 vascular »hot spots« and expressed as
intratumoral microvessel density/mm2 (MVD).
All samples were examined independently by three
specialists in pathology (G. S., D.T. and B. K.) and any dif-
ference was resolved by a joint review.
In the statistical analysis, we used c2-test with Yates
correction, Kruskal-Wallis ANOVA and Mann-Whitney
U-test. The differences were considered statistically sig-
nificant with p<0.05.
Results
In 14 (38.9%) tumor specimens endothelial cells did
not react, weak reaction appeared in 7 (19.4%) speci-
mens, moderate immunohistochemical reaction appea-
red in 5 (13.9%) and strong reaction was noted in 10
(27.8%) specimens (Table 1 and Figures 1 a and b).
Out of the 22 positive specimens, in 3 of them the per-
centage of positive cells was 10%, up to 50% of positive
cells were found in 6 specimens, and over 50% of positive
cells in 13 examined specimens (Table 1).
The ISI was 0 in 14 specimens, I in 3, II in 8, and III in
11 specimens (Table 1).
Of 14 cases with c-myc negative endothelial cells in 7
cases c-myc positivity was observed in tumor cells.
There was no statistically significant association be-
tween gender and ISI (p=0.102), but a statistically sig-
nificant male predominance was observed in cases with a
higher ISI (II and III) (p=0.0483).
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TABLE 1
RELATIONSHIP OF STAINING INTENSITY OF IMMUNOHISTOCHEMICAL REACTION (SI), PERCENTAGE OF POSITIVE CELLS (PPC)
AND IMMUNOSTAINING INTENSITY INDEX (ISI) IN BLOOD VESSEL ENDOTHELIUM OF MEDULLOBLASTOMA
SI PPC ISI
Staining
intensity
Number
of cases
Percentege of
positive cells
Number
of cases
Imunohistochemical
staining index
Number
of cases
0
1
2
3
14
7
5
10
0
1
2
3
14
3
6
13
0
I
II
III
14
3
8
11
36 36 36
Neither MVC nor MVD correlated with SI, PPC and
ISI, respectively (in all cases, p>0.05).
In specimens with weaker SI (groups 0 and 1) MVC
and MVD were significantly lower compared to those in
specimens with a stronger SI (groups 2 and 3) (p=0.023
and p=0.021, respectively) (Table 2).
Neither PPC nor ISI showed a statistically significant
correlation with MVC or MVD (p>0.05).
Discussion and Conclusion
Angiogenesis, as a process of formation of new vascu-
lar spaces and blood supply, is crucial for a tumor cell sur-
vival. New blood vessels grow from pre-existing vascular
spaces by proliferation of endothelial cells which kept the
ability of multiplication and possible endothelial progeni-
tor cells (EPC) present in bone marrow and circulation20.
Factors included in the process of neovascularization can
originate either from tumor cells or from host cells and
act by autocrine or paracrine mechanism. Vascular growth
factor (VEGF), angiopoetin 1 and 2 (Ang-1 and -2),
ephrin (Eph) and Eph tyrosine kinase receptor, platelet
derived growth factor (PDGF), transforming growth fac-
tor (TGF)-b and basic fibroblastic growth factor (bFGF)
belong to this group. Uncontrolled angiogenesis has a
significant role in tumor growth and is an important fac-
tor of malignancy20–27.
An increased c-myc expression is found in many mod-
els of neoplastic transformation. The ability to intensify
angiogenesis as well as lymphangiogenesis supports the
theory of participation of c-myc in metastasizing14,15. The
research on mice has shown that hypoxia is followed by
activation of c-myc and that the level of VEGF rises
markedly compared to control groups, which shows that
c-myc can induce the angiogenesis in vivo across soluble
factors28.
Other authors have shown that the connection of
c-myc and the expression of VEGF and other angiogenic
factors were important for tumor neovascularization. The
c-myc activation itself was sufficient to induce the VEGF
expression and to suppress the expression of antiangio-
genic factors such as thrombospondin 1 (TSP-1). These
facts contribute strongly to the theory that c-myc is im-
portant in angiogenesis and tumor progression13,14,28–30.
Brain tumors of primitive neuroectodermal tumors/
medulloblastomas (PNET/MB) group show the pronoun-
ced neovascularization, and it was shown that tumor
cells produce angiogenic factors, particularly VEGF, which
is important in tumor growth and tumor progression27.
Quantitative analysis and 3D reconstruction of medullo-
blastoma microvasculature indicate that the classical
medulloblastoma type has a dense microvasculature29. In
nodular and desmoplastic type vascular spaces are ar-
ranged around nodular zones, while in giant cell type
they form buds. Mean number of blood vessels is higher
in classical form and medulloblastoma with extensive
nodularity29.
We have not found statistically significant correlation
between the percentage of positive cells and sex of pa-
tients, however, it has been noted that there were more
cases with higher percentage of positive cells in male pa-
tient group; however it was not found statistically signifi-
cant. Less intensive c-myc positivity and blood vessel
density was observed in groups 0 and 1 comparing to
groups 2 and 3.
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TABLE 2
COMPARISON OF C-MYC STAINING INTENSITY IN THE
ENDOTHELIAL CELLS WITH MICROVESSEL COUNT AND
MICROVESSEL DENSITY
c-myc SI N
MVC
(median)
MVDx400/mm2
(median)
0 or I 21 8 (0–32) 2.8 (0–11.4)
II or III 15 13 (6–20) 4.6 (2.1–7.1)
Mann-Whitney
U-test
36 p=0.023 p=0.021
Fig. 1. (a) C-myc expression in the endothelial cells and
(b) in the medulloblastoma cells (200x).
We could conclude that the increased c-myc staining
intensity is connected with a higher amount of blood ves-
sels permm2. If the increased c-myc expression is directly
connected to the expression of angiogenic factors, partic-
ularly of VEGF, that fact can be important in further di-
agnostics and therapy.
It seems that using monoclonal neutralizing antibod-
ies on VEGF, the therapeutic spectrum may be widened
and the possibility of tumor progression as well as of re-
currence reduced31,32.
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EKSPRESIJA C-MYC-a U KAPILARAMA MEDULOBLASTOMA
S A @ E T A K
Pove}ana ekspresija c-myc-a povezana je s neoplasti~nom transformacijom i stvaranjem krvnih `ila. Procjena eks-
presije c-myc-a u endotelnim stanicama i neovaskularizacija mogu pomo}i u procjeni biolo{kog pona{anja tumora. U
na{em radu analizirali smo neovaskularsziaciju i ekspresiju c-myc-a u 36 uzoraka tkiva meduloblastoma. Rezultati su
prikazani semikvantitativno, odre|ivanjem imunohistokemijskog indeksa bojenja (IIB) koji je dobiven kao zbroj inten-
ziteta reakcije (IR) i postotka pozitivnih stanica (PPS). Broj tumorskih krvnih `ila (MVC-microvessel count) dobiven je
na 10 najaktivnih podru~ja neovaskularizacije pri pove}anju od 400x. Broj~ana vrijednost izra`ena je kao gusto}a krv-
nih `ila po mm2 (MVD-microvessel density). Imunohistoelimjski indeks bojanja za c-myc u endotelu krvnih `ila gru-
pirali smo u ~etri grupe, 0 – bez reakcije, I- slaba reakcija (IIB=1 ili 2), II – umjerena reakcija (IIB=3 ili 4), III – jaka
reakcija (IIB=5 ili 6). Statisti~ki zna~ajne razlike (p=0,0214) na{li smo izme|u skupina 0 i 1 u odnosu na skupinu 2 i 3.
Kod pacijenata mu{kog spola na{li smo ve}i postotak reaktivnih stanica nego u pacijenata `enskog spola (p=0,0483).
C-myc PPS 0 ili 1 ima u prosjeku manju gusto}u krvnih `ila po mm2 nego c-myc PPS 2 ili 3, ali razlika nije statisti~ki
zna~ajna. C-myc IIB 0 ili 1 ima u prosjeku manju gusto}u krvnih `ila po mm2 nego c-myc IIB 2 ili 3, ali razlika nije
statisti~ki zna~ajna. Na osnovu rezultata zaklju~ili smo da je intenzitet c-myc bojanja povezan s ve}om gusto}om krvnih
`ila.
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